Marke, Belgium

Jan Delabie


Average Co-Inventor Count = 8.0

ph-index = 2

Forward Citations = 46(Granted Patents)


Location History:

  • Marke, BE (1995)
  • Zwingstraat, BE (1998)

Company Filing History:


Years Active: 1995-1998

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Jan Delabie: Innovator in Cytokine Research

Introduction

Jan Delabie is a notable inventor based in Marke, Belgium. He has made significant contributions to the field of biotechnology, particularly in the area of cytokine research. With a total of 2 patents, his work focuses on the mediators of inflammation and their therapeutic applications.

Latest Patents

Jan Delabie's latest patents revolve around polypeptides with an apparent molecular weight of around 160 kD, which serve as mediators or precursors for mediators of inflammation. These inventions include derivatives such as mutants and fragments, processes for their preparation, DNAs, and hybrid vectors coding for the polypeptides and derivatives. Additionally, he has developed host cells transformed with such hybrid vectors, as well as polyclonal and monoclonal antibodies specific for the polypeptides or their derivatives. His work also encompasses diagnostic and therapeutic methods for inflammatory conditions and Hodgkin lymphomas.

Career Highlights

Throughout his career, Jan Delabie has worked with prominent companies in the pharmaceutical industry, including Novartis Corporation and Ciba-Geigy Corporation. His experience in these organizations has contributed to his expertise in cytokine research and development.

Collaborations

Jan has collaborated with notable professionals in his field, including Karel Gerrit Odink and Lajos Tarcsay. These partnerships have further enhanced his research and innovation capabilities.

Conclusion

Jan Delabie is a distinguished inventor whose work in cytokine research has the potential to impact therapeutic approaches for inflammatory conditions. His contributions to the field are marked by his innovative patents and collaborations with industry leaders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…